{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:25:58Z","timestamp":1794558358927,"version":"4.9.1"},"reference-count":89,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and clinically heterogeneous diseases that cannot be further classified into any other of the existing entities defined by the World Health Organization classification. Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), nowadays represent the standard first-line treatment; for patients who achieve a satisfactory response, a consolidation by means of autologous stem cell transplantation may offer a greater chance of long-term survival. Several patients, however, display treatment refractoriness or relapse soon after obtaining a response, and just a few of them are suitable transplant candidates. This is why several new agents, with innovative mechanisms of action, have been investigated in this context: pralatrexate, romidepsin, belinostat, and brentuximab vedotin have been approved for relapsed and refractory peripheral T-cell lymphomas based on their activity, although they do not significantly affect survival rates. The incorporation of such new drugs within a CHOP backbone is under investigation to enhance response rates, allow a higher proportion of patients to be transplanted in remission, and prolong survival.<\/jats:p>","DOI":"10.1182\/blood-2016-08-692566","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T21:55:15Z","timestamp":1485208515000},"page":"1103-1112","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":98,"title":["Peripheral T-cell lymphoma, not otherwise specified"],"prefix":"10.1182","volume":"129","author":[{"given":"Alessandro","family":"Broccoli","sequence":"first","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. e A. Ser\u00e0gnoli,\u201d University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111903580851400_B1","first-page":"306","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume-title":"World Health Organization classification of tumors of haematopoietic and lymphoid tissues","author":"Pileri","year":"2008","edition":"4th ed"},{"issue":"25","key":"2019111903580851400_B2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111903580851400_B3","first-page":"524","article-title":"T-cell lymphoproliferative disorders","volume-title":"Postgraduate hematology","author":"Zinzani","year":"2016","edition":"7th ed"},{"issue":"3","key":"2019111903580851400_B4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","article-title":"Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets","volume":"117","author":"Piccaluga","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"2019111903580851400_B5","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"issue":"24","key":"2019111903580851400_B6","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","article-title":"Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study","volume":"31","author":"Piccaluga","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111903580851400_B7","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111903580851400_B8","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"2019111903580851400_B9","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111903580851400_B10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"8","key":"2019111903580851400_B11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111903580851400_B12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111903580851400_B13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","article-title":"Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma","volume":"128","author":"Boddicker","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2019111903580851400_B14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma","volume":"20","author":"Streubel","year":"2006","journal-title":"Leukemia"},{"issue":"11","key":"2019111903580851400_B15","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas","volume":"120","author":"Vasmatzis","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111903580851400_B16","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111903580851400_B17","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"19","key":"2019111903580851400_B18","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111903580851400_B19","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bisig","year":"2013","journal-title":"Haematologica"},{"issue":"14","key":"2019111903580851400_B20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111903580851400_B21","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"2019111903580851400_B22","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111903580851400_B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines [abstract]","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111903580851400_B24","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111903580851400_B25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111903580851400_B26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00277-014-2188-8","article-title":"Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients","volume":"94","author":"Xu","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111903580851400_B27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of four prognostic scores in peripheral T-cell lymphoma","volume":"22","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111903580851400_B28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"2019111903580851400_B29","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma","volume":"54","author":"Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2019111903580851400_B30","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.24128","article-title":"Utility of interim and end-of-treatment PET\/CT in peripheral T-cell lymphomas: A review of 124 patients","volume":"90","author":"El-Galaly","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111903580851400_B31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00277-014-2227-5","article-title":"Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma","volume":"94","author":"Tomita","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"2019111903580851400_B32","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00277-013-1782-5","article-title":"The role of 18F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin\u2019s lymphoma patients","volume":"92","author":"Sohn","year":"2013","journal-title":"Ann Hematol"},{"key":"2019111903580851400_B33","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1038\/bcj.2016.2","article-title":"The prognostic value of interim and end-of-treatment PET\/CT in patients with newly diagnosed peripheral T-cell lymphoma","volume":"6","author":"Ham","year":"2016","journal-title":"Blood Cancer J"},{"issue":"7","key":"2019111903580851400_B34","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1634\/theoncologist.2013-0463","article-title":"Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma","volume":"19","author":"Pellegrini","year":"2014","journal-title":"Oncologist"},{"issue":"10","key":"2019111903580851400_B35","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111903580851400_B36","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"issue":"21","key":"2019111903580851400_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4434.4434","article-title":"Patient characteristics and initial treatment patterns in the United States for the most common subtypes of peripheral T-cell lymphoma (PTCL) [abstract]","volume":"124","author":"Pinter-Brown","year":"2014","journal-title":"Blood"},{"key":"2019111903580851400_B38","author":"Abouyabis","year":"2011"},{"key":"2019111903580851400_B39","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","article-title":"The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas","volume":"4","author":"Briski","year":"2014","journal-title":"Blood Cancer J"},{"issue":"2","key":"2019111903580851400_B40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"18","key":"2019111903580851400_B41","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111903580851400_B42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cncr.27733","article-title":"Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350","volume":"119","author":"Mahadevan","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"2019111903580851400_B43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"2019111903580851400_B44","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111903580851400_B45","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111903580851400_B46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111903580851400_B47","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111903580851400_B48","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111903580851400_B49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111903580851400_B50","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111903580851400_B51","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2019111903580851400_B52","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O\u2019Connor","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111903580851400_B53","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111903580851400_B54","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/138920007780655397","article-title":"Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application","volume":"8","author":"Santini","year":"2007","journal-title":"Curr Drug Metab"},{"issue":"22","key":"2019111903580851400_B55","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111903580851400_B56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111903580851400_B57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"9","author":"Foss","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2019111903580851400_B58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-7771-2-16","article-title":"Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma","volume":"2","author":"Foss","year":"2014","journal-title":"Biomark Res"},{"key":"2019111903580851400_B59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"21","key":"2019111903580851400_B60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1748.1748","article-title":"Phase I study of romidepsin in combination with ICE (ifosfamide, carboplatin and etoposide) in patients with relapsed or refractory peripheral T-cell lymphoma [abstract]","volume":"124","author":"Chihara","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2019111903580851400_B61","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"20","key":"2019111903580851400_B62","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111903580851400_B63","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3324\/haematol.2015.135400","article-title":"Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients","volume":"101","author":"Lamarque","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"2019111903580851400_B64","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111903580851400_B65","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111903580851400_B66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111903580851400_B67","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"2019111903580851400_B68","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","article-title":"Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified","volume":"52","author":"Zinzani","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2019111903580851400_B69","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"2019111903580851400_B70","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"2019111903580851400_B71","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1080\/10428190410001683615","article-title":"The expression of the aurora-A gene and its significance with tumorgenesis in non-Hodgkin\u2019s lymphoma","volume":"45","author":"Yakushijin","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2019111903580851400_B72","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1158\/1078-0432.CCR-11-1536","article-title":"Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays","volume":"17","author":"Manfredi","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2019111903580851400_B73","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111903580851400_B74","article-title":"First multicentre, randomized phase 3 study in patients (pts) with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator\u2019s choice (Lumiere trial; NCT01482962) [abstract]","volume":"126","author":"O\u2019Connor","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111903580851400_B75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2013.11.010","article-title":"Allogeneic transplantation in T-cell lymphomas","volume":"51","author":"Schmitz","year":"2014","journal-title":"Semin Hematol"},{"issue":"14","key":"2019111903580851400_B76","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","article-title":"Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire","volume":"26","author":"Le Gouill","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111903580851400_B77","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","article-title":"A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome","volume":"22","author":"Jacobsen","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111903580851400_B78","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","article-title":"Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect","volume":"26","author":"Dodero","year":"2012","journal-title":"Leukemia"},{"issue":"25","key":"2019111903580851400_B79","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111903580851400_B80","article-title":"Allogenic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial [abstract]","volume":"33","author":"Schmitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111903580851400_B81","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/bjh.13855","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial","volume":"172","author":"Advani","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111903580851400_B82","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"23","key":"2019111903580851400_B83","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP phase 1 trial [abstract]","volume":"126","author":"Johnston","year":"2015","journal-title":"Blood"},{"issue":"28","key":"2019111903580851400_B84","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111903580851400_B85","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111903580851400_B86","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111903580851400_B87","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"issue":"21","key":"2019111903580851400_B88","article-title":"First interim efficacy and safety analysis of an international phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with chemotherapy with or without alemtuzumab and consolidated with high dose therapy [abstract]","volume":"120","author":"d\u2019Amore","year":"2012","journal-title":"Blood"},{"key":"2019111903580851400_B89","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.7500","article-title":"Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: final results of 116 patients treated in the international ACT-2 phase 3 trial [abstract]","volume":"34","author":"Trumper","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/9\/1103\/1402758\/blood692566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/9\/1103\/1402758\/blood692566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T03:04:41Z","timestamp":1601435081000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/9\/1103\/36579\/Peripheral-Tcell-lymphoma-not-otherwise-specified"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":89,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,3,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-08-692566","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}